Virtual CME Program
1.00 CME/CE Credit
Bridging the Gap with Dr. Hall: Clinical Inertia and Its Impact on Health Disparities
Clinical inertia is defined as a lack of treatment intensification in a patient not at evidence-based goals for care. Called by some “the enemy to therapeutic success,” clinical inertia essentially causes providers to “drag their feet” in adding additional medications or modalities used to attain treatment goals. Research has shown that communities of color, from several dynamics, suffer more from this phenomenon. We will look at the population outcomes related to diabetes, hypertension, and “watchful waiting” related to cancer diagnoses. Finally, we will look at proven approaches to lowering our tendency as providers to fall into this practice.
- Define clinical inertia and look at its impact across racial/ethnic populations
- Summarize the health disparities in the US for cardiovascular diseases, diabetes management, and cancer treatment attributed to clinical inertia
- Review proven approaches to combating clinical inertia
Gregory L. Hall, MD
Medical Director, Cutler Center for Men, University Hospitals of Cleveland
Associate Professor of Integrative Medical Sciences, Northeast Ohio Medical Center, Rootstown, OH
Associate Professor of Internal Medicine, Northeast Ohio Medical Center, Rootstown, OH
Assistant Clinical Professor in Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
Executive Director, National Institute for African American Health, Cleveland. OH
The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
Gregory L. Hall, MD: No relevant financial relationships disclosed
Moderators and non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.